Yuling Li is the founder of Innoforce Pharmaceuticals. Innoforce Pharmaceuticals has raised $120M in total funding. Latest round: Series A.
Yuling Li is the CEO of Innoforce Pharmaceuticals, a biopharmaceutical innovation company founded in 2018 in Hangzhou, China. The company specializes in developing advanced therapies, including cell and gene therapies, RNA manufacturing platforms, and other biopharmaceutical products. Innoforce Pharmaceuticals has completed a Series A financing round of $96M (625M CNY) in March 2021, co-led by South China Venture Capital and Yanchuang Capital, and a Pre-A financing of $24M (170M CNY) in June 2020. The company's business model involves a structured transaction model with B2B and direct-to-consumer sales, leveraging partnerships with distributors.
Full founder directory · Investor directory · Company funding database · Fundraising library